Hydrogenation process of oxime derivatives
AssigneeSyngenta Crop Protection AG
InventorTomas SMEJKAL
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel process for the iridium-catalysed hydrogenation of oximes. The invention also relates to novel iridium catalysts for use in the iridium-catalysed hydrogenation of oximes and to processes of preparation of these catalysts. The invention further relates to the use of the novel iridium catalysts in ionic hydrogenation of other unsaturated substrates.
Claims13
A process for the hydrogenation of an oxime of formula (I) to produce a hydroxylamine salt of formula (II) by reacting oxime (I) with hydrogen in the presence of an iridium catalyst of formula (IIIa) or formula (IIIb) and an acid;
- wherein R1, R2 and R3 are each independently hydrogen, C1-C8alkyl, C1-C8hydroxyalkyl, C1-C8cyanoalkyl, C1-C6alkoxyC1-C8alkyl, di(C1-C6alkoxy)C1-C8alkyl, C1-C8haloalkyl, C2-C6alkenyl, C3-C8cycloalkyl, phenyl, phenylC1-C3alkyl or heteroaryl, and wherein the cycloalkyl and phenyl moieties are each optionally substituted with 1 to 5 groups selected from hydroxyl, halogen, C1-C6alkyl, C3-C8cycloalkyl, C1-C6haloalkyl, C1-C6alkoxy, phenyl, heteroaryl, C1-C6alkoxycarbonyl, acylamino, amido, cyano, nitro and C2-C6alkenyl;
- or
- R1 and R2 together with the carbon atom to which they are attached may form a 4- to 8-membered saturated cycloalkyl or heterocyclyl ring, wherein the heterocyclic moiety is a non-aromatic monocyclic ring which comprises 1, 2 or 3 heteroatoms, wherein the heteroatoms are individually selected from N, O and S;
- R6, R7, R8, R9 and R10 are each independently hydrogen or C1-C3alkyl;
- represents a bidentate chelating ligand comprising at least one carbon atom which coordinates to iridium and at least one nitrogen atom which coordinates to iridium;
- X represents an anionic group of the formula R14—SO2O— or R15—C(O)O—, wherein
- R14 is hydroxy, C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, or phenyl, wherein the phenyl moieties are optionally substituted by 1, 2, 3 or 4 substituents, which may be the same or different, selected from R16;
- R16 is C1-4alkyl, C1-4haloalkyl, nitro, or halogen;
- R15 is C1-6haloalkyl or phenyl, wherein the phenyl moieties are optionally substituted by 1, 2, 3 or 4 substituents, which may be the same or different, selected from R17;
- R17 is C1-4alkyl, C1-4haloalkyl, nitro or halogen;
- Y represents a neutral ligand;
- and
- Z represents an anionic group.
A compound of formula (IIIc) or (IIId):
- wherein R6, R7, R8, R9 and R10 are each independently selected from hydrogen or C1-C3alkyl;
- R11A, R11B, R11C, R11D, R11E, R13A, R13B, R13C, and R13D are each independently hydrogen, halogen, C1-C8alkyl, C1-C8alkoxy, C1-C8haloalkyl, C1-C8haloalkoxy, hydroxyC1-C8alkoxy, C1-C8alkoxyC1-C6alkoxy, C1-C8alkoxycarbonyl, C1-C8alkoxycarbonylC1-C6alkoxy, C1-C8alkylcarbonylC1-C6alkoxy, phenoxy, or nitro;
- R12 is hydrogen, C1-C8 alkyl or phenyl, wherein each phenyl moiety is optionally substituted by 1 to 5 groups selected from C1-C8alkyl and C1-C8alkoxy;
- or
- R12 and R13D together with the carbon atoms to which they are attached may form a 6- to 8-membered partially saturated cycloalkyl or heterocyclyl ring, wherein the heterocyclic moiety is a non-aromatic ring which comprises 1 or 2 heteroatoms, wherein the heteroatoms are individually selected from N, O and S;
- X is mesylate, tosylate, nosylate, sulfate, hydrogenosulfate, triflate or trifluoroacetate;
- Y is H2O, PhCN or MeCN;
- and
- Z is mesylate, tosylate, nosylate, sulfate, hydrogenosulfate, triflate, tetrafluoroborate, hexafluorophosphate, tetraphenylborate or tetrakis(3,5-bis(trifluoromethyl)phenyl)borate.
Dependencies are inferred from the claim text.